Regulus Therapeutics Inc (RGLS)

2.55 -0.22 (-7.94%) USD  |  NASDAQ  |  Apr 16, 16:00
2.55 0.00 (0.00%) After-Hours: 19:33
More

Regulus Therapeutics Debt to Equity Ratio

Debt to Equity Ratio Chart

Historical Debt to Equity Ratio Data

View and export this data back to 2011. Upgrade now.
Date Value
December 31, 2020 0.1787
September 30, 2020 1.76
June 30, 2020 1.706
March 31, 2020 0.9822
December 31, 2019 0.731
September 30, 2019 -102.28
June 30, 2019 3.083
March 31, 2019 -2.509
December 31, 2018 -2.831
September 30, 2018 12.08
June 30, 2018 1.906
March 31, 2018 0.8688
December 31, 2017 0.5639
September 30, 2017 0.4085
June 30, 2017 0.9917
March 31, 2017 0.5117
December 31, 2016 0.3531
September 30, 2016 0.2722
June 30, 2016 0.2237
Date Value
March 31, 2016 0.00
December 31, 2015 0.00
September 30, 2015 0.00
June 30, 2015 0.00
March 31, 2015 0.00
December 31, 2014 0.1772
September 30, 2014 0.144
June 30, 2014 0.1517
March 31, 2014 0.1452
December 31, 2013 0.1207
September 30, 2013 0.1474
June 30, 2013 0.2959
March 31, 2013 0.2129
December 31, 2012 0.1632
September 30, 2012 -0.3337
June 30, 2012 2.013
March 31, 2012
December 31, 2011 -0.241

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

-102.28
Minimum
Sep 2019
3.083
Maximum
Jun 2019
-13.41
Average
0.9822
Median
Mar 2020

Debt to Equity Ratio Benchmarks

ACADIA Pharmaceuticals Inc 0.00
ADMA Biologics Inc 0.9659
FibroGen Inc -0.3523
Protara Therapeutics Inc --
Amylyx Pharmaceuticals Inc 0.00

Debt to Equity Ratio Related Metrics

Total Assets (Quarterly) 30.75M
Total Liabilities (Quarterly) 9.563M
Shareholders Equity (Quarterly) 21.19M